These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
372 related articles for article (PubMed ID: 32173577)
1. Failure of pre-exposure prophylaxis with daily tenofovir/emtricitabine and the scenario of delayed HIV seroconversion. Lee SS; Anderson PL; Kwan TH; Lui GCY; Chan DPC; Wong NS; Lee KCK; Lam TTN Int J Infect Dis; 2020 May; 94():41-43. PubMed ID: 32173577 [TBL] [Abstract][Full Text] [Related]
2. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report. Hoornenborg E; Prins M; Achterbergh RCA; Woittiez LR; Cornelissen M; Jurriaans S; Kootstra NA; Anderson PL; Reiss P; de Vries HJC; Prins JM; de Bree GJ; Lancet HIV; 2017 Nov; 4(11):e522-e528. PubMed ID: 28919303 [TBL] [Abstract][Full Text] [Related]
3. Updating the Adherence-Response for Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus Pre-Exposure Prophylaxis Among Cisgender Women. Anderson PL; Marzinke MA; Glidden DV Clin Infect Dis; 2023 May; 76(10):1850-1853. PubMed ID: 36645796 [TBL] [Abstract][Full Text] [Related]
4. Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force. Chou R; Evans C; Hoverman A; Sun C; Dana T; Bougatsos C; Grusing S; Korthuis PT JAMA; 2019 Jun; 321(22):2214-2230. PubMed ID: 31184746 [TBL] [Abstract][Full Text] [Related]
5. Short Communication: Tenofovir Disoproxil Fumarate/Emtricitabine Fits for All as Appropriate HIV-1 Pre-Exposure Prophylaxis? Taramasso L; Riccardi N; Del Puente F; Bruzzone B; Ripamonti D; D'Ambrosio B; Viscoli C; Di Biagio A AIDS Res Hum Retroviruses; 2018 Feb; 34(2):168-170. PubMed ID: 29166777 [TBL] [Abstract][Full Text] [Related]
6. Acquisition of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Infection in a Patient Taking Preexposure Prophylaxis. Colby DJ; Kroon E; Sacdalan C; Gandhi M; Grant RM; Phanuphak P; Ananworanich J; Robb ML; Phanuphak N Clin Infect Dis; 2018 Aug; 67(6):962-964. PubMed ID: 29961859 [TBL] [Abstract][Full Text] [Related]
7. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis. Koenig HC; Mounzer K; Daughtridge GW; Sloan CE; Lalley-Chareczko L; Moorthy GS; Conyngham SC; Zuppa AF; Montaner LJ; Tebas P HIV Med; 2017 Jul; 18(6):412-418. PubMed ID: 28444867 [TBL] [Abstract][Full Text] [Related]
8. Brief Report: HIV-1 Evolution in Breakthrough Infections in a Human Trial of Oral Pre-exposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate. Ruone S; Paxton L; McLaurin T; Taylor A; Hanson D; Heneine W; Brooks JT; García-Lerma JG J Acquir Immune Defic Syndr; 2016 Jun; 72(2):129-32. PubMed ID: 26689970 [TBL] [Abstract][Full Text] [Related]
9. Use of Drug-level Testing and Single-genome Sequencing to Unravel a Case of Human Immunodeficiency Virus Seroconversion on Pre-exposure Prophylaxis. Spinelli MA; Lowery B; Shuford JA; Spindler J; Kearney MF; McFarlane JR; McDonald C; Okochi H; Phung N; Kuncze K; Jee K; Johannessen D; Anderson PL; Smith DK; Defechereux P; Grant RM; Gandhi M Clin Infect Dis; 2021 Jun; 72(11):2025-2028. PubMed ID: 32686825 [TBL] [Abstract][Full Text] [Related]
10. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges. Krakower DS; Mayer KH Drugs; 2015 Feb; 75(3):243-51. PubMed ID: 25673022 [TBL] [Abstract][Full Text] [Related]
11. Primary HIV-1 infection in users of pre-exposure prophylaxis. Ambrosioni J; Petit E; Liegeon G; Laguno M; Miró JM Lancet HIV; 2021 Mar; 8(3):e166-e174. PubMed ID: 33316212 [TBL] [Abstract][Full Text] [Related]
12. Early antiretroviral therapy and daily pre-exposure prophylaxis for HIV prevention among female sex workers in Cotonou, Benin: a prospective observational demonstration study. Mboup A; Béhanzin L; Guédou FA; Geraldo N; Goma-Matsétsé E; Giguère K; Aza-Gnandji M; Kessou L; Diallo M; Kêkê RK; Bachabi M; Dramane K; Geidelberg L; Cianci F; Lafrance C; Affolabi D; Diabaté S; Gagnon MP; Zannou DM; Gangbo F; Boily MC; Vickerman P; Alary M J Int AIDS Soc; 2018 Nov; 21(11):e25208. PubMed ID: 31291057 [TBL] [Abstract][Full Text] [Related]
13. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study. Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG; Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098 [TBL] [Abstract][Full Text] [Related]
14. Failure of pre-exposure prophylaxis with on-demand tenofovir disoproxil fumarate/emtricitabine resulting in emergence of antiretroviral resistance. Hsiao YY; Huang YC; Chang SY; Kuo CH; Chang SF; Lin YT; Luo YZ; Lee YL; Hung CC J Microbiol Immunol Infect; 2021 Aug; 54(4):755-757. PubMed ID: 33597075 [No Abstract] [Full Text] [Related]
15. Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE. Vaccher S; Grulich A; McAllister J; Templeton DJ; Bloch M; McNulty A; Holden J; Poynten IM; Prestage G; Zablotska I; BMJ Open; 2016 Jun; 6(6):e012179. PubMed ID: 27324719 [TBL] [Abstract][Full Text] [Related]
16. Maximizing the Benefits of HIV Preexposure Prophylaxis. Buchbinder SP Top Antivir Med; 2018 Apr; 25(4):138-142. PubMed ID: 29689539 [TBL] [Abstract][Full Text] [Related]
17. Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States. Adams JL; Shelley K; Nicol MR Pharmacotherapy; 2019 Apr; 39(4):486-500. PubMed ID: 30815960 [TBL] [Abstract][Full Text] [Related]
18. Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study. Gandhi M; Glidden DV; Mayer K; Schechter M; Buchbinder S; Grinsztejn B; Hosek S; Casapia M; Guanira J; Bekker LG; Louie A; Horng H; Benet LZ; Liu A; Grant RM Lancet HIV; 2016 Nov; 3(11):e521-e528. PubMed ID: 27658870 [TBL] [Abstract][Full Text] [Related]
19. A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine. Cottrell ML; Yang KH; Prince HM; Sykes C; White N; Malone S; Dellon ES; Madanick RD; Shaheen NJ; Hudgens MG; Wulff J; Patterson KB; Nelson JA; Kashuba AD J Infect Dis; 2016 Jul; 214(1):55-64. PubMed ID: 26917574 [TBL] [Abstract][Full Text] [Related]